Lentiviral vectors have the unique ability to efficiently transduce non-dividing cells. Since the majority of the cells in the CNS are post mitotic, recombinant Lentiviral vectors can introduce genes in a variety of cell types including neurons and astrocytes. Lentiviral vectors can also be used to knock-down gene expression using RNA interference (RNAi) technology. The vectors can be generate shRNA to specifically compromise the expression of a target gene. Lentiviral vectors can also be designed to regulate gene expression. Adeno associated viral (AAV) vectors can also be used to introduce genes into the CNS. An advantage of AAV is the ability to generate very high titers of recombinant viruses which can allow easier genetic manipulation of higher animals. In some situations, to identify dividing neurons (neurogenesis), retroviral vectors which transduce only dividing cells will be used. Core B will provide higher titer recombinant viruses to all the investigators. Core B will also offer the possibility of training students and post doctoral fellows in the Pi's laboratory to generate viral vectors. Each PI has indicated their expected needs and we have listed them in Core B text.

Public Health Relevance

This program project will find ways to combat the progression of Alzheimer's disease. The gene delivery systems described in Core B are essential to understand how the progression of this disease can be prevented.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Eleuteri, Simona; Di Giovanni, Saviana; Rockenstein, Edward et al. (2015) Novel therapeutic strategy for neurodegeneration by blocking A? seeding mediated aggregation in models of Alzheimer's disease. Neurobiol Dis 74:144-57
Dhungel, Nripesh; Eleuteri, Simona; Li, Ling-Bo et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on ?-synuclein. Neuron 85:76-87
Blurton-Jones, Mathew; Spencer, Brian; Michael, Sara et al. (2014) Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther 5:46
Vilar, Marçal; Sung, Tsung-Chang; Chen, Zhijiang et al. (2014) Heterodimerization of p45-p75 modulates p75 signaling: structural basis and mechanism of action. PLoS Biol 12:e1001918
Spencer, Brian; Verma, Inder; Desplats, Paula et al. (2014) A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. J Biol Chem 289:17917-31
Overk, Cassia R; Cartier, Anna; Shaked, Gideon et al. (2014) Hippocampal neuronal cells that accumulate ?-synuclein fragments are more vulnerable to A? oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Mol Neurodegener 9:18
Overk, Cassia R; Masliah, Eliezer (2014) Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 88:508-16
Dubal, Dena B; Yokoyama, Jennifer S; Zhu, Lei et al. (2014) Life extension factor klotho enhances cognition. Cell Rep 7:1065-76
Sekiyama, Kazunari; Waragai, Masaaki; Akatsu, Hiroyasu et al. (2014) Disease-Modifying Effect of Adiponectin in Model of ?-Synucleinopathies. Ann Clin Transl Neurol 1:479-489
Games, Dora; Seubert, Peter; Rockenstein, Edward et al. (2013) Axonopathy in an ýý-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated ýý-synuclein. Am J Pathol 182:940-53

Showing the most recent 10 out of 150 publications